Next-generation balloon-expandable Myval transcatheter heart valve in low-risk aortic stenosis patients.

Aged Aged, 80 and over Aortic Valve / diagnostic imaging Aortic Valve Stenosis / diagnostic imaging Female Heart Valve Prosthesis Humans Male Prosthesis Design Retrospective Studies Transcatheter Aortic Valve Replacement / adverse effects Treatment Outcome

TAVR aortic stenosis balloon-expandable

Journal

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions

ISSN: 1522-726X

Titre abrégé: Catheter Cardiovasc Interv

Pays: United States

ID NLM: 100884139

Informations de publication

Date de publication:
02 2022

Historique:

revised: 26 07 2021

received: 05 05 2021

accepted: 02 08 2021

pubmed: 15 8 2021

medline: 8 4 2022

entrez: 14 8 2021

Statut: ppublish

Résumé

We aimed to describe hemodynamic performance and clinical outcomes at 30-day follow-up of the balloon-expandable (BE) Myval transcatheter heart valve (THV) in low-risk patients. The results of the next-generation BE Myval THV in low-risk aortic stenosis (AS) patients are still unknown. Retrospective registry performed in nine European centers including patients with low predicted operative mortality risk according to Society of thoracic surgeons (STS) and European system for cardiac operative risk evaluation (EuroSCORE-II) scores. Between September 2019 and February 2021, a total of 100 patients (51% males, mean age 80 ± 6.5 years) were included. Mean STS score and EuroSCORE-II were 2.4 ± 0.8% and 2.2 ± 0.7%, respectively. Intermediate sizes were used in 39% (21.5 mm: 8%, 24.5 mm: 15%, 27.5 mm: 15%). There were no cases of valve embolization, coronary artery occlusion, annulus rupture, or procedural death. A definitive pacemaker implantation was needed in eight patients (8%). At 30-day follow-up aortic valve area (0.7 ± 0.2 vs. 2.1 ± 0.6 cm Hemodynamic performance and 30-day clinical outcomes of the BE Myval THV in low-risk AS patients were favorable. Longer-term follow-up is warranted.

Sections du résumé

OBJECTIVES

We aimed to describe hemodynamic performance and clinical outcomes at 30-day follow-up of the balloon-expandable (BE) Myval transcatheter heart valve (THV) in low-risk patients.

BACKGROUND

The results of the next-generation BE Myval THV in low-risk aortic stenosis (AS) patients are still unknown.

METHODS

Retrospective registry performed in nine European centers including patients with low predicted operative mortality risk according to Society of thoracic surgeons (STS) and European system for cardiac operative risk evaluation (EuroSCORE-II) scores.

RESULTS

Between September 2019 and February 2021, a total of 100 patients (51% males, mean age 80 ± 6.5 years) were included. Mean STS score and EuroSCORE-II were 2.4 ± 0.8% and 2.2 ± 0.7%, respectively. Intermediate sizes were used in 39% (21.5 mm: 8%, 24.5 mm: 15%, 27.5 mm: 15%). There were no cases of valve embolization, coronary artery occlusion, annulus rupture, or procedural death. A definitive pacemaker implantation was needed in eight patients (8%). At 30-day follow-up aortic valve area (0.7 ± 0.2 vs. 2.1 ± 0.6 cm

CONCLUSIONS

Hemodynamic performance and 30-day clinical outcomes of the BE Myval THV in low-risk AS patients were favorable. Longer-term follow-up is warranted.

Identifiants

DOI: 10.1002/ccd.29923 PMID: 34390296

pubmed: 34390296

doi: 10.1002/ccd.29923

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

889-895

Informations de copyright

Références

Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the Management of Patients with Valvular Heart Disease. J Am Coll Cardiol. 2021;77(4):e25-e197.

Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705.

Sharma SK, Rao RS, Chandra P, et al. First-in-human evaluation of a novel balloon-expandable transcatheter heart valve in patients with severe symptomatic native aortic stenosis: the MyVal-1 study. EuroIntervention. 2020;16(5):421-429.

Rao RS. Safety and effectiveness of next-generation balloon-expandable transcatheter heart valve: six-month results of MyVal-1 study. Presented as Late Breaking Trial at: EuroPCR; May 19-22, 2020.

Kawashima H, Wang R, Mylotte D, et al. Quantitative angiographic assessment of aortic regurgitation after transcatheter aortic valve implantation among three balloon-expandable valves. Glob Heart. 2021;16(1):20. https://doi.org/10.5334/gh.959

Delgado-Arana JR, Gordillo-Monge MX, Halim J, et al. Early clinical and haemodynamic matched comparison of balloon-expandable valves. Heart. 2021. https://doi.org/10.1136/heartjnl-2021-319349. [Epub ahead of print].

Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research consortium-2 consensus document. J Thorac Cardiovasc Surg. 2013;145(1):6-23.

Thyregod HGH, Steinbrüchel DA, Ihlemann N, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial. J Am Coll Cardiol. 2015;65(20):2184-2194.

Kawashima H, Soliman O, Wang R, et al. Rationale and design of a randomized clinical trial comparing safety and efficacy of myval transcatheter heart valve versus contemporary transcatheter heart valves in patients with severe symptomatic aortic valve stenosis: the LANDMARK trial. Am Heart J. 2021;232:23-38. https://doi.org/10.1016/j.ahj.2020.11.001